Investors shouldn't rush to buy the stock based on rosy short-term price targets.To say that Exact Sciences (EXAS 3.19%) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street.Cathie Wood is one of them. The investment firm she heads, Ark Invest, holds over 330,000 shares of Exact Sciences. She isn't the only one who isn't giving up on the company. Analysts on Wal ...

We are almost halfway through 2024, and the stock market is putting on a masterclass performance. The S&P 500 is up 12% year-to-date after rising 23% last year. Back-to-back years of double-digit gains make finding stocks that can continue on such a torrid trajectory difficult.Yet analysts at Jefferies Financial Group (NYSE:JEF) have zeroed in on a handful of stocks they think can maintain that pace. Within the past two weeks, they plucked these three stocks for double-digit returns over the next 12 months. ...

A month has gone by since the last earnings report for Exact Sciences (EXAS) . Shares have lost about 17.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Exact Sciences Q1 Revenues Rise Y/Y, Gross ...

Exact Sciences (EXAS) continues to be impacted by escalating expenses and fierce competition.Exact Sciences has been grappling with escalated expenses for a while. Deteriorating international trade stemming from complex geopolitical environments across the globe is leading to a tough situation related to raw material and labor costs as well as freight charges. The stock carries a Zacks Rank #4 (Sell) currently.Further, the continuous rise in interest rates through 2023 with no news from the Fed of a rate cu ...

Exact Sciences Corporation (EXAS) will present 10 abstracts demonstrating the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 31 to Jun 4, 2024. The data that will be provided expands the body of evidence surrounding the predictive and prognostic utility of the Oncotype DX test in all racial and ethnically diverse patients.Exact Sciences will also present data on their approach to multi-canc ...

With the S&P 500 sitting just a few points below setting a new all-time high, the bull market that began in 2022 is still snorting. Although a correction or even a bear market will eventually happen, the market is content to run higher. With the benchmark index up 11% year-to-date (YTD), it is 48% higher since the bull began charging in 2022.There could be more to come. Much more. Bear markets tend to be short-term events lasting about 15 months on average. However, bull markets are measured in years. They ...

The ARK Innovation ETF (NYSEARCA:ARKK) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year.One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks. This approach allows the fund to make significant investments in companies that ARK Invest believes have the potential to revolutionize their respective industries. However, this concentrati ...

Exact Sciences Corporation (EXAS) reported a net loss of 50 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate. This quarter's loss was wider than the year-ago loss of 42 cents.Revenues in DetailFirst-quarter consolidated revenues were $637.5 million, up 5.8% on reported and core revenue basis year over year. The metric exceeded the Zacks Consensus Estimate by 2%.Segments in DetailScreening revenues, including laboratory service revenues from Cologuard, PreventionGenetics and i ...

Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Erik Holznecht - Manager, IR Kevin Conroy - Chairman and CEO Jeff Elliott - CFO Aaron Bloomer - EVP of Finance Everett Cunningham - Chief Commercial Officer Conference Call Participants Catherine Schulte - Baird Vijay Kumar - Evercore ISI Doug Schenkel - Wolfe Research Patrick Donnelly - Citi Dan Arias - Stifel Jack Meehan - Nephron Research Andrew Brackmann - William Blair Puneet Souda - Le ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this molecular diagnostics company would post a loss of $0.53 per share when it actually produced a loss of $0.27, delivering a surprise of 49.06%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Exact Sciences, whi ...